Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: Doug Meetmer who wrote (366)	7/15/1998 3:54:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 717

Doug, Can't say it makes much sense to me, but here is an extract from the 9/97 H&Q report: "Given that peripheral arteries are much larger in diameter than arteries in the heart where most of the angioplasties are done, we are not expecting that any efficacy will be seen in this phase I study. However, we also expect that Lu-Tex angioplasty technique in this indication will demonstrate a clean safety profile, paving the way for efficacy studies to commence in both peripheral and cardiac arteries in 1998. With over 600,000 angioplasties performed annually in the US at an average cost of $25,000 per procedure, this is a huge potential market opportunity, but given its early stage of development, it can only be viewed as a wild card. " BTW, some H&Q PCYC reports, including the one from which the above extract was taken, (but not the most recent update) is available at the Signal site: recap.com Peter